Navigation Links
Researchers shed light on mechanism of action used by anti-cancer drug

Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new mechanism of action of the anti-cancer drug sorafenib, which could stimulate the development of novel regimens in which it is combined with other molecularly targeted agents for patients with blood cancers and solid tumors.

In the new study, led by Steven Grant, M.D., Massey’s associate director for translational research and co-leader of the cancer center’s cancer cell biology program, VCU researchers identified a mechanism by which sorafenib inhibits protein translation, and which may be involved in reducing expression of pro-survival factors, such as Mcl-1, and other proteins. The findings were published online in the journal Molecular and Cellular Biology on June 4.

According to Grant, sorafenib, or Nexavar which is manufactured by Bayer Pharmaceuticals, has recently been approved for the treatment of patients with renal cell cancer, the most common form of kidney cancer in adults. It was originally developed as an inhibitor of the oncogene, Raf, which is frequently mutated in numerous cancers, including leukemia. Oncogenes are typically responsible for promoting tumor growth.

Previous findings by Grant’s team, reported in the Journal of Biologic Chemistry, showed that in human leukemia cells, sorafenib lethality was less a consequence of Raf inhibition, but rather reflected interference with the synthesis of Mcl-1. They found that sorafenib interfered with Mcl-1 translation, a process in which proteins are synthesized from their constituent amino acids. However, the mechanism by which protein translation was inhibited by sorafenib remained largely unknown.

In the present work, Grant and his team found that in human leukemia cells, sorafenib induces a process known as endoplasmic reticulum (ER) stress, which results from accumulation of misfolded proteins in the ER. The ER is a subcellular structure which plays a key role in cellular pr
'"/>

Source:Virginia Commonwealth University


Page: 1 2

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain

Post Your Comments:
(Date:11/24/2009)...RK (November 24, 2009) -- The Wildlife Conservatio... that the last remaining population of Siberian ti...rising tide of poaching and habitat loss. , ...an officials of what needs to be done to protect r..., The report was released by the Sib...
(Date:11/23/2009)... presents strong evidence that the "synergistic" e...ic-related pollution and indoor endotoxin causes m... exposure alone. , Environmental health scient...of Medicine have shown that children exposed to bo...door endotoxin during early life are six times mor...
(Date:11/23/2009)... than 160 participants gathered this week for the ...TIATIVE conference. This year,s topic, "Synthetic ...and medical researchers to explore the engineering...erging field of synthetic biology. , Bonnie L. B...n University and this year,s conference chair, cha...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Majority of Public Maintains Support for Addressing Health Care Reform Now 52480 1Majority of Public Maintains Support for Addressing Health Care Reform Now 52480 2Majority of Public Maintains Support for Addressing Health Care Reform Now 52480 3Majority of Public Maintains Support for Addressing Health Care Reform Now 52480 4Majority of Public Maintains Support for Addressing Health Care Reform Now 52480 5KLOS 26 Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 52478 1KLOS 26 Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 52478 2KLOS 26 Red Cross Set to Rock SoCal With Massive 5 Day Blood Drive 52478 3E Cigarettes Pose a Health Hazard FDA Warns 52474 1E Cigarettes Pose a Health Hazard FDA Warns 52474 2E Cigarettes Pose a Health Hazard FDA Warns 52474 3
...rs at the UC Davis M.I.N.D. Institute has found th... children born in California with autism since 199... condition is diagnosed or counted and the trend ...ary 2009 issue of the journal Epidemiology , resu...ld shift from genetics to the host of chemicals an...
...nal that publishes original research contributions... of entomology, plant pathology, virology, nematol...gicides, herbicides and other biocides. Emphasis ...iseases. , Phytoparasitica also publishes invit...t editorials written by reputable scientists attes...
... Prevention Research , a journal of the American A...nts of black raspberries with chemopreventive pote...ive Cancer Center found that anthocyanins, a class...wth and stimulated apoptosis in the esophagus of r...r data provide strong evidence that anthocyanins a...
Other Biology News:Study shows California's autism increase not due to better counting, diagnosis 2Study shows California's autism increase not due to better counting, diagnosis 3Springer expands its portfolio in plant sciences with Phytoparasitica 2
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...RNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ...ommercializingnovelpainmanagementtherapies,announc...veOfficer,isscheduledtopresentatthe21stAnnualPiper...09atTheNewYorkPalaceHotelinNewYork,NewYork. ,, ...r,willbeavailabletorespondtoquestionsduringthepres...
(Date:11/24/2009)...asbeenmetforpatientswithadvanced-stage,orrecurrent...wire-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;...panyfocusedonendocrinetherapyandoncology,todayanno...rgetedcytotoxicpeptideconjugate,AEZS-108(formerlyA...lcancer.Inapersonalizedhealthcareapproach,thestudy...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--GenomicHealth,Inc.(Nasdaq...,sExecutiveChairman,willpresentatthe21stAnnualPipe...,December1,2009at10:00a.m.ET. ,, Toaccesstheliv...isittheInvestorRelationssectionofGenomicHealth,swe...onnecttothewebsiteatleast15minutespriortothebeginn...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2
...FRANCISCO, March 12 VIA Pharmaceuticals, Inc. (Na... the development of compounds for the treatment of...nced it has entered into a $10.0 million secured n...llary agreements, the "Loan Agreement") with Bay C...s (collectively, "Lender"), the Company,s principa...
... A significant challenge utili... the cost and uncertainty associated with vectors ...roblem, DNA2.0 has developed a new family of vecto...s. pJexpress vectors are specifically engineered t...own to express better than comparable pET vectors....
...ADELPHIA, March 12 ERT, a leading provider of cen...ther services to the biopharmaceutical, medical de... it will be showcasing its portfolio of products a... DIA Euromeeting, 23-25 March 2009 in Berlin, Germ...ing sessions, which will discuss the impact of tec...
Other Biology Technology:VIA Pharmaceuticals Secures Financing Up to $10.0 Million 2VIA Pharmaceuticals Secures Financing Up to $10.0 Million 3VIA Pharmaceuticals Secures Financing Up to $10.0 Million 4DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors 2DNA2.0 Introduces Freedom of Expression With a New Family of Bacterial Expression Vect:ors 3ERT to Showcase Its Clinical Trials Portfolio at DIA's 21st Euromeeting 2ERT to Showcase Its Clinical Trials Portfolio at DIA's 21st Euromeeting 3
Uniblot accessories from Sigma-Aldrich
StemSep Anti-Human CD69 Tetramer, 200 uL from StemCell Technologies, Inc.
Aquarius 384 Multichannel Pipettor from Tecan
...nx software, a multitasking application capable of...amming and operation of lab automation workcells e...tom modification by programmers. • Users cr...wchart. If you can build a flowchart, you can writ...
Biology Products: